1.57
+4.67%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Clarity Pharmaceuticals
Its shares trade on ASX under the ticker CU6.AX. It has been listed since 25 August 2021. In the fiscal year to 30 June 2025, it reported revenue of A$9.5m and a net loss of A$64.3m. At that date it held total assets of A$101.2m and shareholders' equity of A$90.2m.
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Aug 2021
- Website
- claritypharmaceuticals.com ↗
Leadership
Pay as last reported
- Dr. Alan TaylorExecutive Chairman of the Board, since 2013A$3.2m
- Ms. Michelle ParkerChief Executive Officer, Managing Director, Executive DirectorA$1.1m
- Mr. David GreenChief Financial Officer
- Dr. Colin BigginChief Operating Officer, Executive Director, since 2019A$1.6m
- Ms. Eva LengyelovaExecutive Vice President - Clinical Development
- Dr. Matthew HarrisChief Scientific Officer
- Dr. Othon GervasioChief Medical Officer
- Mr. Robert VickeryCompany Secretary
- Ms. Rosanne RobinsonLead Independent Non-Executive DirectorA$205,949
- Dr. Thomas RamdahlNon-Executive DirectorA$183,140
- Dr. Christopher RobertsNon-Executive DirectorA$189,922
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clarity Pharmaceuticals Ltd. focuses on theranostic products using SAR Technology platform.
- Seven clinical trials are progressing with three key products SARTATE, SAR-bisPSMA, and SAR-Bombesin.
- Products address both large indications like NETs and rare orphan indications for cancer treatment.
Weaknesses
- The company is a clinical stage firm with no commercialized products yet.
- Seven clinical trials require significant financial resources and time to complete.
- No established market presence in the pharmaceutical sector as a new entrant.
Opportunities
- SARTATE targets neuroblastoma and NETs, large market indications for cancer diagnosis.
- SAR-bisPSMA addresses PSMA-expressing cancers, a growing segment in oncology.
- SAR-Bombesin identifies GRPr-expressing cancers, including breast and prostate cancer markets.
Threats
- Clinical trial failures could delay product approvals and market entry.
- Competition from established pharmaceutical companies in oncology markets.
- Regulatory hurdles may impact the approval timeline for new therapeutics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.